Second Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
ESMO Open. 2020 May;5(3):e000646. doi: 10.1136/esmoopen-2019-000646.
We sought to determine the prognostic role of indoleamine 2,3-dioxygenase 1 () by evaluating expression in circulating tumour cells (CTCs) at baseline and after completion of chemoradiotherapy in patients with locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) treated with curative intent.
In a prospective cohort of 113 patients with LA HNSCC, we evaluated expression of in the EpCAM+ CTC fraction at baseline and after cisplatin chemoradiation. The prognostic value of combined () and expression was assessed.
was significantly overexpressed at baseline compared with the post-treatment counterparts (p=0.007). messenger RNA (mRNA) expression at baseline was associated with better survival in terms of progression-free survival (PFS) (HR=0.19, p=0.017). Post-treatment mRNA levels were correlated with unfavourable prognosis in terms of overall survival (OS) (HR=3.27, p=0.008). Patients with combined decreased expression levels of and after treatment exhibited superior PFS (p=0.043) and OS (p=0.021).
Our results strongly suggest that mRNA expression is an independent prognostic factor for clinical outcome. Our study provides useful information for future trials combining chemoradiation with immune checkpoint inhibitors and IDO1 inhibitors.
我们旨在通过评估局部晚期（LA）头颈部鳞状细胞癌（HNSCC）患者在接受根治性放化疗后基线和完成放化疗后的循环肿瘤细胞（CTC）中吲哚胺 2,3-双加氧酶 1（IDO1）的表达，来确定其预后作用。
在一项前瞻性队列研究中，我们评估了 113 例 LA HNSCC 患者的 IDO1 在 EpCAM+CTC 亚群中的表达水平，分别在基线和顺铂放化疗后进行评估。联合评估（）和表达的预后价值。
与治疗后相比，基线时显着过表达（p=0.007）。基线时信使 RNA（mRNA）表达与无进展生存期（PFS）的生存相关（HR=0.19，p=0.017）。治疗后 mRNA 水平与总生存期（OS）的不良预后相关（HR=3.27，p=0.008）。治疗后联合表达水平降低的患者的 PFS（p=0.043）和 OS（p=0.021）明显改善。
我们的研究结果强烈表明，IDO1 mRNA 表达是临床结局的独立预后因素。我们的研究为未来联合放化疗与免疫检查点抑制剂和 IDO1 抑制剂的试验提供了有用的信息。
